Xencor Inc (NASDAQ:XNCR) insider Paul A. Foster sold 5,000 shares of the company’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $25.01, for a total value of $125,050.00. Following the completion of the sale, the insider now owns 7,419 shares in the company, valued at $185,549.19. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Shares of Xencor Inc (XNCR) opened at $25.40 on Monday. Xencor Inc has a 1 year low of $18.55 and a 1 year high of $28.64. The firm has a market capitalization of $1,190.00, a price-to-earnings ratio of -25.15 and a beta of 1.97.
A number of analysts have weighed in on XNCR shares. Canaccord Genuity set a $36.00 price target on Xencor and gave the company a “buy” rating in a research report on Monday, October 23rd. ValuEngine cut Xencor from a “hold” rating to a “sell” rating in a research report on Monday, October 23rd. Zacks Investment Research cut Xencor from a “hold” rating to a “sell” rating in a research report on Saturday, November 11th. Piper Jaffray Companies reiterated a “buy” rating and issued a $35.00 price target on shares of Xencor in a research report on Sunday, November 12th. Finally, Cantor Fitzgerald started coverage on Xencor in a research report on Wednesday, November 29th. They issued an “overweight” rating and a $33.00 price target on the stock. Two research analysts have rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company. Xencor currently has a consensus rating of “Hold” and an average target price of $30.80.
ILLEGAL ACTIVITY WARNING: “Insider Selling: Xencor Inc (XNCR) Insider Sells 5,000 Shares of Stock” was originally reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.com-unik.info/2018/02/19/insider-selling-xencor-inc-xncr-insider-sells-5000-shares-of-stock.html.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.